These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Pharmacogenetic explanation for excessive beta-blockade following timolol eye drops. Potential for oral-ophthalmic drug interaction. Edeki TI; He H; Wood AJ JAMA; 1995 Nov 22-29; 274(20):1611-3. PubMed ID: 7474246 [TBL] [Abstract][Full Text] [Related]
4. [Effects of 3 topically administered beta blockers on the rabbit crystalline lens]. Eckerskorn U; Wegener A; Hockwin O; Fournes C; Ermisch S; Müller P; Möller B Fortschr Ophthalmol; 1988; 85(2):139-43. PubMed ID: 2899043 [No Abstract] [Full Text] [Related]
5. Evaluation of the anti-Acanthamoeba activity of two commercial eye drops commonly used to lower eye pressure. Sifaoui I; Reyes-Batlle M; López-Arencibia A; Wagner C; Chiboub O; De Agustino Rodríguez J; Rocha-Cabrera P; Valladares B; Piñero JE; Lorenzo-Morales J Exp Parasitol; 2017 Dec; 183():117-123. PubMed ID: 28778743 [TBL] [Abstract][Full Text] [Related]
6. Topical beta-adrenergic antagonists and quinidine. A risky interaction. Higginbotham EJ Arch Ophthalmol; 1996 Jun; 114(6):745-6. PubMed ID: 8639090 [No Abstract] [Full Text] [Related]
7. Association of CYP2D6 single-nucleotide polymorphism with response to ophthalmic timolol in primary open-angle Glaucoma--a pilot study. Yuan H; Yu M; Yang Y; Wu K; Lin X; Li J J Ocul Pharmacol Ther; 2010 Oct; 26(5):497-501. PubMed ID: 20925579 [TBL] [Abstract][Full Text] [Related]
8. Topical timolol and lipid profile. Manoher JM; Sharma AK; Sahai R Indian J Ophthalmol; 1995 Jun; 43(2):73-4. PubMed ID: 8818314 [TBL] [Abstract][Full Text] [Related]
9. Effect of timolol and UF-021 (a prostaglandin-related compound) on pulsatile ocular blood flow in normal volunteers. Kitaya N; Yoshida A; Ishiko S; Mori F; Abiko T; Ogasawara H; Kato Y; Nagaoka T Ophthalmic Res; 1997; 29(3):139-44. PubMed ID: 9211466 [TBL] [Abstract][Full Text] [Related]
10. [Corneal sensitivity after single doses of timolol, betaxolol or placebo in persons with healthy eyes--a randomized, prospective double-blind study]. Höh H Fortschr Ophthalmol; 1988; 85(2):132-8. PubMed ID: 2899042 [No Abstract] [Full Text] [Related]
11. Effects of topical nipradilol and timolol maleate on intraocular pressure, facility of outflow, arterial blood pressure and pulse rate in dogs. Maehara S; Ono K; Ito N; Tsuzuki K; Seno T; Yokoyama T; Yamashita K; Izumisawa Y; Kotani T Vet Ophthalmol; 2004; 7(3):147-50. PubMed ID: 15091320 [TBL] [Abstract][Full Text] [Related]
12. [A clinico-pharmacological study of an ophthalmic drug form of proxodolol]. Ermakova VN Eksp Klin Farmakol; 1994; 57(3):57-9. PubMed ID: 7914124 [TBL] [Abstract][Full Text] [Related]
13. The role of hyaluronan as a drug carrier to enhance the bioavailability of extended release ophthalmic formulations. Hyaluronan-timolol ionic complexes as a model case. Battistini FD; Tártara LI; Boiero C; Guzmán ML; Luciani-Giaccobbe LC; Palma SD; Allemandi DA; Manzo RH; Olivera ME Eur J Pharm Sci; 2017 Jul; 105():188-194. PubMed ID: 28506871 [TBL] [Abstract][Full Text] [Related]
14. Optic nerve vasomotor effects of topical beta-adrenergic antagonists in rabbits. Orgül S; Mansberger S; Bacon DR; Van Buskirk EM; Cioffi GA Am J Ophthalmol; 1995 Oct; 120(4):441-7. PubMed ID: 7573301 [TBL] [Abstract][Full Text] [Related]